Edo Vellenga

Research interests

Publications

• Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes

  New England Journal of Medicine · 2020 · https://doi.org/10.1056/nejmoa1908892

• Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial

  Leukemia · 2017 · https://doi.org/10.1038/leu.2017.211

• Bortezomib Induction and Maintenance Treatment in Patients With Newly Diagnosed Multiple Myeloma: Results of the Randomized Phase III HOVON-65/ GMMG-HD4 Trial

  Journal of Clinical Oncology · 2012 · https://doi.org/10.1200/jco.2011.39.6820

• BLUEPRINT to decode the epigenetic signature written in blood

  Nature Biotechnology · 2012 · https://doi.org/10.1038/nbt.2153

• Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)

  Blood · 2011 · https://doi.org/10.1182/blood-2011-08-376087

• Clinical significance of CD56 expression in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based regimens

  Blood · 2010 · https://doi.org/10.1182/blood-2010-04-277434

• Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients

  Blood · 2010 · https://doi.org/10.1182/blood-2009-12-261032

• Clinical, Molecular, and Prognostic Significance of WHO Type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and Various Other 3q Abnormalities in Acute Myeloid Leukemia

  Journal of Clinical Oncology · 2010 · https://doi.org/10.1200/jco.2010.29.2771

• High-Dose Daunorubicin in Older Patients with Acute Myeloid Leukemia

  New England Journal of Medicine · 2009 · https://doi.org/10.1056/nejmoa0901409

• A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma

  Blood · 2009 · https://doi.org/10.1182/blood-2009-05-222539

• Risk-adapted treatment of acute promyelocytic leukemia with all-trans retinoic acid and anthracycline monochemotherapy: long-term outcome of the LPA 99 multicenter study by the PETHEMA Group

  Blood · 2008 · https://doi.org/10.1182/blood-2008-05-159632

• Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin

  Blood · 2008 · https://doi.org/10.1182/blood-2007-07-100669

• Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors

  Blood · 2008 · https://doi.org/10.1182/blood-2008-07-168617

• Treatment of newly diagnosed acute promyelocytic leukemia (APL): a comparison of French-Belgian-Swiss and PETHEMA results

  Blood · 2007 · https://doi.org/10.1182/blood-2007-07-099978

• Prognostic Index for Adult Patients With Acute Myeloid Leukemia in First Relapse

  Journal of Clinical Oncology · 2005 · https://doi.org/10.1200/jco.2005.06.027

Current projects

No projects listed.